Navigation Links
tellic Launches drug360 Knowledge Graph to Unlock Genetic Insights from Biomedical Data

drug360 graph, a breakthrough knowledge graph product, has just been released by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language processing and machine learning to bear on biomedical big data. This new tool allows researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and other biomedical entities. Researchers and analysts can use drug360 graph to dramatically increase their efficiency searching multiple data sources and uncover valuable genetic knowledge supporting decisions around their pipelines.

“drug360 graph provides greater confidence around the crucial decisions researchers make regarding advancing drug candidates or abandoning them,” says Richard Wendell, tellic CEO. “Research shows that genetic evidence can double the chances of a clinical trial’s success.”

drug360 graph contains proprietary data on 180 million relationships between diseases, genes, gene variants, phenotypes, and other biomedical entities. This data is generated by tellic’s patent-pending deep learning algorithms, which scan biomedical text to extract entities, normalize them to the desired concept within biomedical ontologies, and quantify the strength of relationships. Quantifying the strength of these relationships is crucial, because it helps remove the “noise” from the signal. “tellic’s proprietary deep learning technologies incorporate biomedical context which results in high quality genetic evidence data that can improve clinical trial success,” says Wendell.

With drug360 graph, researchers can:

  • Immediately be up and running with a biomedical knowledge graph pre-populated with 180 million genetic relationships
  • Easily import their internal data into tellic’s proprietary data to create a Knowledge Graph that is unique to their organization
  • Quickly identify unexpected genetic linkages to inform target selection, clinical trial design, BD and biotech investment decisions.
  • Drill down and search genetic relationships of interest to pinpoint each sentence in the source data that was used to generate the relationship
  • Export search results into a CSV or Excel for further analysis

drug360 currently contains millions of additional relationships between genes or gene variants than those found in public databases. Available as software as a service, the product is easy to use and is well supported.

About tellic
Big data, machine learning, and natural language processing are brought together by tellic into drug360 to form a single, unparalleled source of clear-cut insights about associations between genes and diseases. The company was founded in 2015 by Richard Wendell, a Fortune 500 Chief Data Officer, whose vision was to make it easy for pharma companies to apply emerging data science technologies to their pipelines. tellic pioneers a new category of enterprise-scale biomedical language processing and knowledge discovery powered by machine learning. For more information or to arrange a demo of drug360 graph, please contact

Additional Contact:
Ryan Leventhal
VP, Business Development
Direct: 212-221-8612
SOURCE: tellic

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
2. IntelliCyt Launches iQue® Screener PLUS to Accelerate Suspension-cell Screening and Combinatorial Profiling for Immunological Applications
3. Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
4. SpectraGenetics Joins IntelliCyt’s Technology Alliance Partner Program
5. IntelliCyt Corporation Completes $7.4 Million in New Financing
6. IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment
7. AstraZeneca Enters into an Agreement with IntelliCyt for the Development of High Throughput Biology Applications
8. Massachusetts General Hospital Enters Into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
9. IntelliCyt Announces a New Addition to the iQue® Screener PLUS Platform During CYTO 2016
10. Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
11. IntelliCyt Launches Novel Assay System to Accelerate Cell Line Development
Post Your Comments:
(Date:1/27/2020)... PORTLAND, Ore. (PRWEB) , ... January 27, 2020 ... ... the latest advances in neuroscience and cloud and mobile computing, today announced the ... leaders from across an organization to use the latest neuroscience of leadership and ...
(Date:1/24/2020)... SOUTH RIDING, Va. (PRWEB) , ... January 24, ... ... analytics, and other innovations created by companies in biotechnology, diagnostics, therapeutics, laboratory and ... the lives of millions of people around the world. And as Slone ...
(Date:1/22/2020)... MATEO, Calif. (PRWEB) , ... January 20, 2020 ... ... System, today announced a partnership with WAVE Electronics, the largest independent electronics distributor ... installer partners to purchase Brilliant Smart Home Systems with leading smart home products ...
(Date:1/22/2020)... Conn. (PRWEB) , ... January 21, 2020 , ... ... (CTC) liquid biopsy from a simple blood draw, today announced the sale of the ... Health. The Rare Scope will be used in clinical cancer research. , “The RareScope ...
Breaking Biology Technology:
(Date:1/28/2020)... ... January 28, 2020 , ... ... companies and government agencies, announced that the firm has established a presence in ... Cambridge office will be in the Cambridge Innovation Center (CIC), at One Broadway ...
(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus Therapeutics Inc. today ... tech entrepreneur, and former senior management consultant at McKinsey & Company who holds ... alternative investment firm. , “Chris Thorne has exceptional business acumen with a ...
(Date:1/24/2020)... ... January 24, 2020 , ... Worldwide Business with kathy ireland® ... Stanbridge and Vice President of Sales and Marketing Jeff Maier to discuss their innovative ... content on Sunday, Jan. 26, 2020 at 5:30 p.m. EST and internationally on Bloomberg ...
Breaking Biology News(10 mins):